Navigation Links
Vaccines for Ovarian and Breast Cancer in Early Trials
Date:1/11/2008

Activating body's immune system should fight tumors, researchers say

FRIDAY, Jan. 11 (HealthDay News) -- Therapeutic vaccines to fight ovarian and breast cancer are in the first stage of clinical trials to determine their safety and effectiveness, researchers report.

The vaccine for ovarian cancer, developed by Dr. George Coukos, an assistant professor at the University of Pennsylvania's division of gynecologic oncology, is designed to "re-educate" the patient's immune system cells to destroy cancer cells.

"This trial is a phase I/II trial that is just getting started," Coukos said during a presentation Thursday evening at a meeting of the Alliance for Cancer Gene Therapy, in Greenwich, Conn. The trial will include some 30 women with ovarian cancer.

The vaccine makes use of the patients' own tumor cells, which are then put into the patients' own dendritic cells. Dendritic cells are responsible for initiating the body's immune response, Coukos said.

In this trial, two new drugs -- called DCVax-L and DCVax-L primed -- are being used to aid in growing new immune cells. The trial is also testing which of the drugs is most effective.

The "re-educated" dendritic cells are then injected back into the patient at intervals spanning as long as three years, according to Coukos. Once in the body, these cell are designed to attack the cancer cells.

Using this therapy in mice produced dramatic results, Coukos said. "Typically, the translation from mouse to human is always disappointing," he said. "We are hoping, based on other clinical data, there will be a good response."

By creating individualized ovarian cancer vaccines composed of a patient's own cells, Coukos believes that his tailored approach will be effective. "We actually use the patient's own tumor and the patient's own blood. So it's not one-type-of-therapy-fits-all. Everybody gets their own individualized treatment," he said.

As with all early trials, the outcome isn't assured. "We need to keep trying," Coukos said. "One trial will not provide all the answers we need."

There were some 22,430 new cases of ovarian cancer diagnosed in the United States in 2007, and approximately 15,280 deaths from the disease, according to American Cancer Society estimates. In most cases of ovarian cancer, the disease has already reached late stage and spread beyond the ovaries before it is detected and diagnosed. Because the cancer has spread to other parts of the body -- metastasized -- the prognosis is typically not good, Coukos said.

After surgery and chemotherapy, late-stage ovarian cancer usually recurs in 18 months to 20 months. When it does reappear, it is considered incurable and usually results in death, even with aggressive chemotherapy, Coukos noted.

In another presentation at the meeting, Dr. Leisha A. Emens, an assistant professor of oncology at Johns Hopkins University, discussed her work on a new therapeutic vaccine to fight breast cancer.

Of the six types of breast cancer, the vaccine is designed to treat HER-2/neu disease, which is particularly aggressive. The vaccine is designed to marshal the body's immune response to fight the cancer, she said.

Emens has also found that combining the vaccine with currently used chemotherapy drugs such as cyclophosphamide and doxorubicin increased the vaccine's effectiveness. In the current trial, women with advanced breast cancer are receiving combinations of vaccine and chemotherapy.

Emens said she's also working on a vaccine that, along with chemotherapy, would prevent blood vessels from feeding the cancer, essentially starving and killing the cancer cells.

"We have enrolled eight folks and have seen evidence for immunity," Emens said. "It is important that now that we are on the verge of developing immune-based and gene-therapy-based approaches for treating cancer to integrate these novel approaches into the standards we already have, so we can maintain the progress and improve it." she said. "By doing that, we will be able to cure breast cancer in our lifetime."

Breast cancer is the most common cancer among American women, other than skin cancer, and is the second leading cause of cancer death in women, after lung cancer. About 178,480 U.S. women will be diagnosed with invasive breast cancer this year, and about 40,460 will die from the disease, according to the American Cancer Society.

The Alliance for Cancer Gene Therapy says it's the only public charity in the United States that is dedicated exclusively to cancer gene therapy research, with 100 percent of funds raised by the group going directly to research.

More information

For more on ovarian cancer, visit the U.S. National Cancer Institute.



SOURCES: George Coukos, M.D., Ph.D., assistant professor of obstetrics and gynecology, University of Pennsylvania, Philadelphia; Leisha A. Emens, M.D., Ph.D., assistant professor of oncology, Johns Hopkins University, Baltimore; Jan. 10, 2008, presentation, Alliance for Cancer Gene Therapy, Greenwich, Conn.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Human Papilloma Virus vaccines may decrease chances of oral cancer
2. CDC Study Links Thimerosal in Vaccines to Motor/Phonic Tics and Deficits in Attention, Behavior Control, Verbal IQ
3. Novartis Vaccines Launches National Gift-Giving Program to Help Protect Loved Ones by Reserving an Influenza Vaccination
4. Combination vaccines okay for infants, study shows
5. Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
6. Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
7. Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
8. St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases
9. Study Shows Cholera Can be Controlled With Oral Vaccines
10. Pneumococcal conjugate vaccines can improve the lives of HIV-infected children
11. New study suggests why vaccines directed against cancer, HIV dont work
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vaccines for Ovarian and Breast Cancer in Early Trials
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and Financial ... financial preparation services, is providing an update on a charitable event that began ... Rescue is a locally recognized nonprofit that provides shelter and care for animals ...
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology: